
Fellow @UAMSHealth , IM Residency @balladhealth , Research fellow @pennmedicine @keckmedicineUSC , @ASCO Featured voice , Visiting Resident @MDAndersonnew
Little rock, AR
Joined December 2023
- Tweets1.4K
- Following435
- Followers587
- Likes11.7K
Pinned Tweet
Reuniting with my mentor is a dream come true! An awe-inspiring moment with this dynamic GI oncologist 💕👑
Women empowering women. The art of mentorship , sponsership and allyship.. @WomeninOnc @ASCO @UAZCancer @UAZHemeOnc
Supriya peshin retweeted
🚨🔥@OncoAlert Hot Off The Press.
Just presented @myESMO #ESMO26 by @sands_jacob the long-awaited #PracticeChanging results of:
⭐️ #DeLLphi305 phase 3 trial of:
❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab.
Study showed:
‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit.
✅#mOS: 21.1 vs 12.7 months (HR 0.42)
✅12-month OS: 79.4% vs 53.3%
✅#mPFS: 7.4 vs 1.9 months (HR 0.34)
✅#ORR: 26.4 % vs 4.1%
✅ Safety Data:
⚠️ Grade ≥3 #AEs: 46.8% vs 40.6%
* In Tarlatamab arm:
#CRS: 49.6% (Grade ≥3: 0.4%)
#ICANS: 1.1% (Grade ≥3: 0%)
🚨🔥@OncoAlert Hot off the press.
Just published @NEJM in conjunction with presentation @myESMO #ESMO26
the long-awaited #PracticeChanging results of:
⭐️#DeLLphi305 phase 3 trial of:
❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab.
Study showed:
‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit.
✅#mOS: 21.1 vs 12.7 months (HR 0.42)
✅12-month OS: 79.4% vs 53.3%
✅#mPFS: 7.4 vs 1.9 months (HR 0.34)
⚠️ Grade ≥3 #AEs: 46.8% vs 40.6%
* In Tarlatamab arm:
#CRS: 49.6% (Grade ≥3: 0.4%)
#ICANS: 1.1% (Grade ≥3: 0%)
👇🏻
nejm.org/doi/full/10.1056/NE…
Supriya peshin retweeted
And the room rises! What a moment for the team and the patients at the heart of this work! 👏 #ESMO26 @oncoalert @myESMO @DanaFarber @sands_jacob
Supriya peshin retweeted
It is with heavy hearts that we share that Dr. Rachna Shroff has passed away. A longtime partner of CCF, she has made tangible differences for patients and their families throughout her career. From being a valued member of our Science and Medical Advisory Board to helping build one of the nation's largest clinical and research programs in biliary tract cancer as a faculty member at MD Anderson Cancer Center, and as an empathetic and expert clinician, she made a difference in every facet.
Beyond her professional accomplishments, she brought fun everywhere she went. Whether she was quoting Beyoncé in a talk about clinical trials or getting us to throw our hands during her amazing Bollywood lesson, Rachna made us live in the moment and laugh, even in the hardest of times. Our hearts are with her family and friends in the days ahead and beyond.
Supriya peshin retweeted
📖Our systematic review found that #metabolic syndrome may be linked more strongly to aggressive #ProstateCancer than to overall incidence, underscoring the need for standardized prospective research now!
Link to the paper🧷mdpi.com/2072-6694/18/12/195…
Supriya peshin retweeted
Can’t believe we’re having a full session on KRAS G12D targeted therapy in pancreatic cancer! So glad to see how far we’ve come.
@DrShubhamPant @DAVAOnc @BaptistHealthSF @BHAcademics @MiamiCancerInst
Dr. @Sarbaji85064063 of @BaptistHealthSF discussed setidegrasib, a KRAS G12D-targeted degrader in pancreatic cancer, highlighting its mechanism, phase 1 efficacy and safety data, and ongoing phase 3 evaluation in first-line metastatic PDAC. #DAVAGI
Supriya peshin retweeted
If done correctly , this could broaden access to Tarlatamab for the wider community. I do believe we need better risk categorization of patients for CRS/ICANs and more access to remote monitoring resources/ investment into education of community ER/Urgent care doctors for toxicity recognition etc. 👏 #lcsm #SCLCM
amgen.com/newsroom/press-rel…
📚 Excited to share our review on KRAS-targeted therapies in pancreatic cancer. Daraxonrasib (RMC-6236) is especially promising, demonstrating a significant survival benefit over chemotherapy in previously treated patients with metastatic PDAC. A meaningful step toward making precision oncology a reality in pancreatic cancer. mdpi.com/4081322 #mdpicancers via @Cancers_MDPI @EhabTakrori @shafiarahman_ @HamediZahra @uamscancer @OSUhemoncfellow @GiOncNow @oncodaily @IMG_Oncologists @letswinpc
Supriya peshin retweeted
Tarlatamab is coming to the first line!
📢 #SCLC news: Amgen announced that a Phase 3 study evaluating its DLL3-targeting therapy as part of first-line maintenance treatment for patients with extensive-stage small cell lung cancer met its primary endpoint
➡️ Learn more: amgen.ly/4ihHq5p
$AMGN
Supriya peshin retweeted
🆕👇🏽Unveiling FULL results of our #NEST🪺 Trial in MSS “cold”🧊colorectal cancer
💡Immunotherapy (BOT🤖/BAL) BEFORE surgery
💯% disease-free to date✅
NEST1:~32 months
NEST2:~24 months
5 years of work—now in @CCR_AACR🙌🏽
🚀#NEST3 NOW OPEN!
@OncoAlert
🔗 aacrjournals.org/clincancerr… – at Irvine, CA
📖🔖Small Cell Lung Cancer: New advances, new hope.
From immunotherapy and durvalumab to tarlatamab and emerging biomarkers, the SCLC landscape is evolving. Yet treatment resistance and poor long-term survival remain major challenges. @EhabTakrori @aditdharia @Cancers_MDPI @IMG_Oncologists @oncodaily
mdpi.com/4022082 #mdpicancers via @Cancers_MDPI
Supriya peshin retweeted
💡Our review, "A Review of #Immunotherapy in #Renal Cell Carcinoma: Current Landscape and Future Directions," highlights the evolving role of immunotherapy and emerging #treatment strategies in #RCC.
by @supriyadocc et al.
Read for free🔎mdpi.com/2072-6694/17/19/313…
Publication 📚 Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: a systematic review
frontiersin.org/journals/onc…
@shafiarahman_ @EhabTakrori @IbrahimSahinMD1 @HamediZahra @oncodaily @IMG_Oncologists @FrontOncology @GiOncNow
Supriya peshin retweeted
What drives immunotherapy response in renal cell carcinoma? @supriyadocc and colleagues ask in this new editorial for BMJ Oncology
🔗 bmjoncology.bmj.com/content/…
Supriya peshin retweeted
ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response.
Read the full article. bit.ly/445AKPr
Supriya peshin retweeted
ERRFI1-mutant cholangiocarcinoma may represent a rare actionable subgroup for EGFR-targeted therapy.
In a 14-patient retrospective multicenter BTC study, all cases were intrahepatic cholangiocarcinoma. Among 8 patients treated with EGFR TKIs, best responses included 3 PRs, 4 SDs, and 1 PD.
@supriyadocc @Fen_Saj @pashtoonkasi @JavleMilind @MiteshBorad @DrShubhamPant
oncodaily.com/oncolibrary/ga…
#Cholangiocarcinoma #BTC #EGFR #ERRFI1
Does metabolic health influence prostate cancer outcomes? Our systematic review suggests metabolic syndrome particularly obesity and insulin resistance may be more strongly associated with aggressive prostate cancer than with cancer incidence itself.
mdpi.com/3937200 @Cancers_MDPI @KArnaoutakis @Dr_Bhavesh_M @AnuradhaKuntur1 @EhabTakrori @uamscancer @UAMS
Supriya peshin retweeted
ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response | JCO Precision Oncology ascopubs.org/doi/10.1200/PO-…
Supriya peshin retweeted
took off hospice to give Erlotinib💊.
🆕@JCOPO_ASCO
💡Such a beautiful story of real world🌎 precision medicine.
Meet➡️#ERRFI1🎯
📝Time to add➕this to ACTIONABLE Biomarkers🔐for #cholanagiocarcinoma @curecc. @NCCN
👇🏽Patient in paper, I took off hospice to give Erlotinib💊.
@OncoAlert
🔗ascopubs.org/doi/10.1200/PO-…
Supriya peshin retweeted
⭐️ Evolving Paradigms in Metastatic #PancreaticCancer
🎙️Treatment landscape, toxicities, +emerging 🤩 RAS-targeted therapies‼️
🎙️@OncBrothers discuss with @MallaMidhun, Dr. Morse, Dr. Musher & @JanieYZhang
#pcsm #OncTwitter #MedTwitter #Oncology #medX
oncupdates.com/video-podcast…





































